Plus Therapeutics: New CNSide Team, Volatile Stock & Cautious Investor Outlook
Explore Plus Therapeutics’ latest CNSide Diagnostics expansion, its volatile biotech stock, and what the numbers mean for investors in 2025.
2 minutes to read
Plus Therapeutics Inc